Clinical Trials Logo

Diagnoses Disease clinical trials

View clinical trials related to Diagnoses Disease.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06439901 Not yet recruiting - Diagnoses Disease Clinical Trials

Optimizing Bronchopulmonary Cancer Screening

OPTI-DEPIST
Start date: June 30, 2024
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the feasibility of performing a first screening for bronchopulmonary cancer by thoracic scanner in a French cohort within a dedicated, effective and strutured network in the pilot centers participating in the study.

NCT ID: NCT06306430 Not yet recruiting - Tuberculosis Clinical Trials

Detection of Lipoarabinomannan in Urine Evaluation of the STANDARDTMF TBLAMFIA and Its Impact on the Initial TB Diagnosis

uLAMTBFIA
Start date: May 2024
Phase:
Study type: Observational

Evaluation of the performance of an in vitro test, the STANDARDTM F TB LAM Ag FIA (SD BIOSENSOR, INC.) for the early diagnosis of tuberculosis (TB) infection. This test is for in vitro professional diagnostic use and intended as an aid to early diagnosis of tuberculosis infection. The test will be used according to the instructions for use (IFU).

NCT ID: NCT05600608 Not yet recruiting - Gastric Cancer Clinical Trials

Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma From the Tumour Lipidome

AVOCADO
Start date: November 2022
Phase: N/A
Study type: Interventional

Nearly 10,000 people die each year in the United Kingdom from cancer of the lower gullet and stomach, known as known as oesophago- gastric adenocarcinoma (OGC). OGC is detected late as symptoms are non- specific and often mistaken for common problems such as heartburn. This translates to fewer than 2 in every 10 patients diagnosed with OGC living longer than 5 years. The breath of people with OGC is enriched with volatile chemicals (VOCs) that indicate cancer. When measured in a breath test, it detects OAC 80 out of 100 times. Whilst encouraging, there is scope to improve the detection rate by giving patients a stimulant drink that amplifies the production of tumour specific VOCs only, to increase their detection in the breath test. The goal of this observational study is to produce an enhanced second-generation breath test with superior ability to detect OGC through augmentation of breath. This will improve long term survival from cancer using an entirely non- invasive test. All participants (cancer and control participants) will consume an oral stimulant drink (OSD) and provide breath samples pre and post consumption of the drink at set time points (maximum 2 hours after consumption of the drink). The investigators will compare the breath VOCs from both groups, before and after consumption of the OSD to see if the OSD has a desired augmentation effect and can improve the accuracy of the OGC breath test. With this second-generation breath test, participants with vague symptoms can undergo a quick, non- invasive test, have samples analysed in a safe and accurate manner and be subsequently stratified based on their risk of having OGC, leading to earlier disease detection and improved clinical outcomes.

NCT ID: NCT05434611 Not yet recruiting - Diagnoses Disease Clinical Trials

Role of Calcium Binding Protein S100A12 in Diagnosis and Prognosis of Kawasaki Disease

Start date: July 1, 2022
Phase:
Study type: Observational

Recent studies showed that the value of c100A12 increased in children with Kawasaki disease, and decreased rapidly after treatment with gamma globulin. In kawasaki disease with coronary artery dilatation, S100A12 levels are elevated in the acute phase of Kawasaki disease and continue for some time in the convalescence phase before gradually decreasing. However, the number of patients included in previous studies was small and the follow-up time was short. In this study, 100 children with Kawasaki disease who were admitted to Wuhan Children's Hospital, Jingzhou First People's Hospital and Renhe Hospital affiliated to China Three Gorges University from December 2021 to December 2023 were selected as the research objects, and 100 children with healthy physical examination were selected as the control group during the same period. To investigate whether S100A12 increased significantly in the acute phase of Kawasaki disease compared with a healthy control group. To study whether S100A12 value increased rather than decreased in kawasaki disease that did not respond to gamma globulin treatment after gamma globulin treatment. At the same time, to study whether the increase of S100A12 in kawasaki disease convalescence indicates coronary aneurysm.

NCT ID: NCT05064566 Not yet recruiting - Diagnoses Disease Clinical Trials

Evaluation of Caries Detection Methods

Start date: October 20, 2021
Phase:
Study type: Observational

The investigators aim will be to compare the diagnostic performance of clinical visual examination (ICDAS II), intraoral/bite wing radiography (BW), near infrared light transillumination (NIR-LT), and laser fluorescence (LF), in comparison to microcomputed tomography (micro-CT) for the detection of non-cavitated occlusal enamel and dentin caries in third molar teeth. Potential participants will be consecutively recruited.

NCT ID: NCT04985188 Not yet recruiting - Diagnoses Disease Clinical Trials

Quantitative Ultrasound for Diagnosing Hepatic Steatosis in Nonalcoholic Fatty Liver Multicenter Study

Start date: August 12, 2021
Phase:
Study type: Observational

To evaluate the diagnostic performance of quantitative ultrasound parameters for assessing hepatic steatosis in non-alcoholic fatty liver disease using histologic results as reference standard

NCT ID: NCT04605042 Not yet recruiting - Clinical trials for Pancreatic Neoplasms

Comparsion of WT and SNP Techniques of EUS-FNB in Pancreatic Solid Mass (WESP-PSM)

WESP-PSM
Start date: December 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the diagnosis accuracy between of wet suction (WS) technique and standard negative pressure (SNP) technique in EUS-FNB by 22G EUS Procore fine needle biopsy(FNB)device for solid pancreatic lesions.

NCT ID: NCT04401644 Not yet recruiting - Coronavirus Clinical Trials

COVID-19: Laser Interferometry for Rapid Single Coronavirus Detection

COLIDE
Start date: June 2020
Phase: N/A
Study type: Interventional

Using Laser light to detect COVID 19 virus particles in deep throat swab / nasal swab samples.

NCT ID: NCT04035174 Not yet recruiting - Diagnoses Disease Clinical Trials

Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa

EOLoa
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This study aims at evaluating the diagnosis performances of the LTS-2 DEC patch for onchocerciasis compared to the gold standard which are the skin snips. This study will be conducted in Cameroon in two different areas : Ngog-Mapubi and Bafia Health Districts (one area only endemic for onchocerciasis, and one area endemic for both loiasis and onchocerciasis).

NCT ID: NCT03967652 Not yet recruiting - Cancer Clinical Trials

Cancer Diagnoses From Exhaled Breath With Na-nose

Start date: July 1, 2019
Phase:
Study type: Observational

Early diagnoses of malignant tumors are pivotal for improving their prognoses. The Exhaled Breath is made up of oxygen, carbon dioxide, nitrogen, water, inert gases and volatile organic compounds (VOCs). Theoretically, the concentration of VOCs in exhalation produced by metabolism in human body is only about nmol/L-pmol/L, which can significantly increase under certain pathological conditions. A series of studies of VOCs diagnosing solid tumors the investigators had been conducted in the past decade. It was found that VOCs in exhaled breath can not only distinguish different types of tumors, but also can make a clear distinction between different stages. Our long-term collaborator, Professor Hossam Haick (Israel Institute of Technology) has developed a nano sensor array, so called Na-nose, which can detect VOCs of the exhaled breath by binding gases to specific chemiresistors coated with gold nanomaterials. The Na-nose has the advantages of low cost, easy to use, good reproducibility and real-time detection for large scale clinical application. This study was to use large clinical samples to validate the diagnostic efficacy of the newly developed Nano-nose( Sniffphone and Breath Screener) for malignant tumors .